Published online December 1, 2004
PEDIATRICS Vol. 114 No. 6 December 2004, pp. 1601-1605 (doi:10.1542/peds.2004-0092)
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow An erratum has been published
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via ISI Web of Science (39)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Weinzimer, S. A.
Right arrow Articles by Tamborlane, W. V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Weinzimer, S. A.
Right arrow Articles by Tamborlane, W. V.
Related Collections
Right arrow Endocrinology

Persistence of Benefits of Continuous Subcutaneous Insulin Infusion in Very Young Children With Type 1 Diabetes: A Follow-up Report

Stuart A. Weinzimer, MD*, JoAnn H. Ahern, MSN, APRN*, Elizabeth A. Doyle, MSN, APRN*, Miranda R. Vincent, MSN, APRN*, James Dziura, PhD{ddagger}, Amy T. Steffen, BS* and William V. Tamborlane, MD*,{ddagger}

* Department of Pediatrics
{ddagger} Children's Clinical Research Center, Yale University School of Medicine, New Haven, Connecticut

Objective. Use of continuous subcutaneous insulin infusion (CSII) has increased dramatically in recent years, and pump therapy has been shown to be a safe and effective alternative to multiple daily injections in adults and older pediatric patients with type 1 diabetes. Its use in very young children, however, has been limited, although this group might be expected to benefit the most from CSII. The objective of this study was to analyze the CSII efficacy and safety data in very young children with type 1 diabetes from our Diabetes Clinic database.

Methods. Glycosylated hemoglobin (HbA1c), severe hypoglycemia (SH), and ketoacidosis (DKA) in the year before CSII were compared with corresponding values during pump treatment in all children who started CSII before age 7.

Results. Sixty-five children (mean age: 4.5 y at CSII initiation; range: 1.4–6.9 years; 28 girls; 3 black, 1 Hispanic) were analyzed for >162 patient-years of follow-up. Mean HbA1c (7.4 ± 1.0 prepump) decreased to 7.0 ± 0.9 after 12 months of CSII and continued to improve even after 4 years on CSII. The rate of SH was reduced by 53% (from 78 to 37/100 patient-years). Children who received daytime care from paid caregivers (n = 26) experienced significant reductions in HbA1c and hypoglycemia frequency. There were no episodes of DKA requiring emergency treatment in the year before CSII and 4 episodes (4 per 100 patient-years) after transition to pump.

Conclusions. CSII is a durable and effective means of optimizing glycemic control in very young patients with type 1 diabetes and may be superior to multiple daily injections in minimizing the risk of severe hypoglycemia in this age group. Employment of paid caregivers does not preclude safe and effective use of CSII.

Key Words: continuous subcutaneous insulin infusion • insulin pump therapy • type 1 diabetes • children

Abbreviations: CSII, continuous subcutaneous insulin infusion • HbA1c, glycosylated hemoglobin • BMI, body mass index • SH, severe hypoglycemia • DKA, diabetic ketoacidosis

Accepted Jun 21, 2004.




This article has been cited by other articles:


Home page
 Diabetes CareHome page
S. A. Weinzimer, C. Ternand, C. Howard, C.-T. Chang, D. J. Becker, L. M.B. Laffel, and for the Insulin Aspart Pediatric Pump Study Group
A Randomized Trial Comparing Continuous Subcutaneous Insulin Infusion of Insulin Aspart Versus Insulin Lispro in Children and Adolescents With Type 1 Diabetes
Diabetes Care, February 1, 2008; 31(2): 210 - 215.
[Abstract] [Full Text] [PDF]

Home page
 Arch. Dis. Child.Home page
T. Danne, K. Lange, and O. Kordonouri
New developments in the treatment of type 1 diabetes in children
Arch. Dis. Child., November 1, 2007; 92(11): 1015 - 1019.
[Full Text] [PDF]

Home page
 Diabetes CareHome page
M. Phillip, T. Battelino, H. Rodriguez, T. Danne, F. Kaufman, and for the Consensus forum participants
Use of Insulin Pump Therapy in the Pediatric Age-Group: Consensus statement from the European Society for Paediatric Endocrinology, the Lawson Wilkins Pediatric Endocrine Society, and the International Society for Pediatric and Adolescent Diabetes, endorsed by the American Diabetes Association and the European Association for the Study of Diabetes
Diabetes Care, June 1, 2007; 30(6): 1653 - 1662.
[Full Text] [PDF]

Home page
 Diabetes CareHome page
P.-M. Holterhus, R. Odendahl, S. Oesingmann, R. Lepler, V. Wagner, O. Hiort, R. Holl, and the German/Austrian DPV Initiative and the German
Classification of Distinct Baseline Insulin Infusion Patterns in Children and Adolescents With Type 1 Diabetes on Continuous Subcutaneous Insulin Infusion Therapy
Diabetes Care, March 1, 2007; 30(3): 568 - 573.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
J. R. Wood, E. C. Moreland, L. K. Volkening, B. M. Svoren, D. A. Butler, and L. M.B. Laffel
Durability of insulin pump use in pediatric patients with type 1 diabetes.
Diabetes Care, November 1, 2006; 29(11): 2355 - 2360.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
E. A. Eugster, G. Francis, and and the Lawson-Wilkins Drug and Therapeutics Commi
Position Statement: Continuous Subcutaneous Insulin Infusion in Very Young Children With Type 1 Diabetes
Pediatrics, October 1, 2006; 118(4): e1244 - e1249.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
R. Nimri, N. Weintrob, H. Benzaquen, R. Ofan, G. Fayman, and M. Phillip
Insulin pump therapy in youth with type 1 diabetes: a retrospective paired study.
Pediatrics, June 1, 2006; 117(6): 2126 - 2131.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
T. Berhe, D. Postellon, B. Wilson, and R. Stone
Feasibility and safety of insulin pump therapy in children aged 2 to 7 years with type 1 diabetes: a retrospective study.
Pediatrics, June 1, 2006; 117(6): 2132 - 2137.
[Abstract] [Full Text] [PDF]

Home page
 The Diabetes EducatorHome page
S. Owen
Pediatric Pumps: Barriers and Breakthroughs
The Diabetes Educator, January 1, 2006; 32(1): 29S - 38S.
[Full Text] [PDF]

Home page
 The Diabetes EducatorHome page
L. K. Fisher and M. Halvorson
Future Developments in Insulin Pump Therapy: Progression From Continuous Subcutaneous Insulin Infusion to a Sensor-Pump System
The Diabetes Educator, January 1, 2006; 32(1): 47S - 52S.
[Full Text] [PDF]

Home page
 Evid. Based Nurs.Home page
L. Lowes
Parents of children with diabetes described the transition to the insulin pump in terms of enhanced freedom and quality of life for all family members
Evid. Based Nurs., October 1, 2005; 8(4): 124 - 124.
[Full Text] [PDF]

Home page
 The Diabetes EducatorHome page
E. A. Doyle (Boland), A. T. Steffen, and W. V. Tamborlane
Case Study: Contrasting Challenges of Insulin Pump Therapy in a Toddler and Adolescent With Type 1 Diabetes
The Diabetes Educator, July 1, 2005; 31(4): 584 - 590.
[Abstract] [Full Text] [PDF]

Home page
 CLIN PEDIATRHome page
S. A. Weinzimer, E. A. Doyle, and W. V. Tamborlane Jr
Disease Management in the Young Diabetic Patient: Glucose Monitoring, Coping Skills, and Treatment Strategies
Clinical Pediatrics, June 1, 2005; 44(5): 393 - 403.
[Abstract] [PDF]